References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [4]
References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [4]
author: Keqing Pan, Yang Hu, Yufeng Wang, Hao Li, Michele Patel, Danyang Wang, Zuomin Wang, Xiaozhe Han | publisher: drg. Andreas Tjandra, Sp. Perio, FISID
Tu S, Zhong D, Xie W, Huang W, Jiang Y, Li Y. Role of toll-like receptor signaling in the pathogenesis of graft-versus-host diseases. Int J Mol Sci. 2016;17(8).
Gaddis DE, Michalek SM, Katz J. TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B. J Immunol. 2011;186(10):5772–83.
Zhang P, Liu J, Xu Q, et al. TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-kappaB. J Biol Chem. 2011;286(27):24159–69.
Xie YF, Shu R, Jiang SY, et al. miRNA-146 negatively regulates the production of pro-inflammatory cytokines via NF-kappaB signalling in human gingival fibroblasts. J Inflamm (Lond). 2014;11(1):38.
Zhang J, Jia G, Liu Q, et al. Silencing miR-146a influences B cells and ameliorates experimental autoimmune myasthenia gravis. Immunology. 2015;144(1):56–67.
Meisgen F, Xu Landen N, Wang A, et al. MiR-146a negatively regulates TLR2-induced inflammatory responses in keratinocytes. J Invest Dermatol. 2014;134(7):1931–40.
Zhang B, Wang A, Xia C, Lin Q, Chen C. A single nucleotide polymorphism in primary-microRNA-146a reduces the expression of mature microRNA-146a in patients with Alzheimer’s disease and is associated with the pathogenesis of Alzheimer’s disease. Mol Med Rep. 2015;12(3):4037–42.
Serial posts:
- Abstract : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Abstract : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Background : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Background : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Methods : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Methods : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Methods : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [3]
- Results : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Results : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Discussion : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Discussion : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Conclusions : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Availability of data and materials : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Abbreviations : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [3]
- References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [4]
- Acknowledgements : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Funding : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Author information : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Author information : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Ethics declarations : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Additional information : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Supplementary information : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Rights and permissions : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- About this article : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Table 1 Success rate (SR) of osseointegrated implants 4 weeks after implant placement : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Fig. 1. Mouse model of ligature-induced experimental peri-implantitis. (a) Tooth extraction: left maxillary first and second molars extracted at 4 weeks old and the tooth extraction socket healed well with smooth gingiva surface after 6 weeks post-extraction. Implant placement: implant was put in alveolar bone without flap elevation. Ligature placement: at 4 weeks post-implant, 7-0 ligatures were applied under the fixture head. Gingival injection: injections for animals were administered three times on days 3, 6, and 9 during 14 days ligation period. Sample collection: 14 days post-ligation, the gingival tissues and the skulls were collected. (b) Images depicting processing steps of the experimental design (scale bar, 500 μm) : RANKL blockade alleviates peri-implant
- Fig. 2. Anti-RANKL and anti-RANKL+miR-146a treatments decreased ligature-induced bone resorption with different patterns in experimental peri-implantitis of WT and TLR2/4 KO mice. Buccal side images of the defleshed skulls were taken of the control (non-ligation) group, ligation (non-treatment) group, ligation with anti-RANKL antibody (ligation+AR) treatment group, and ligation with anti-RANKL antibody + miR-146a (ligation+A+MiR) treatment group in WT mice and TLR2/4 KO mice (a) (scale bar, 500 μm). The bone resorption area based on these images was measured and analyzed for WT mice (b) and TLR2/4 KO mice (c) (mean ± SD, n = 6, *p < 0.05, **p < 0.01, SEM, standard error of difference between two means). Three dimension (3D) images from μCT were collected and analyzed for WT mice (d) and TLR4 KO mice (e) (mean ± SD, n = 6, *p < 0.05, **p < 0.01) : RANKL blockade alleviates peri-implant
- Fig. 3. Anti-RANKL and anti-RANKL+miR-146a treatments decreased TRAP-positive cell quantities with different patterns in experimental peri-implantitis of WT and TLR2/4 KO mice. TRAP-positive cells (red color) with 3 or more nuclei were considered osteoclasts and were shown in the control group, ligation group, ligation with anti-RANKL antibody treatment group, and ligation with anti-RANKL antibody + miR-146a treatment group in WT mice and TLR2/4 KO mice (a) (Im, implant; Av, alveolar bone; scale bar, 100 μm). The quantities of TRAP-positive cells were analyzed in each group of WT mice (b) and TLR2/4 KO mice (c) (mean ± SD, n = 6, **p < 0.01) : RANKL blockade alleviates peri-implant
- Fig. 4. Anti-RANKL and anti-RANKL+miR-146a treatments decreased the inflammatory cell infiltration of the implant gingival tissues with different patterns in experimental peri-implantitis of WT and TLR2/4 KO mice. HE staining of the gingival tissue around implants were performed in the control group, ligation group, ligation with anti-RANKL antibody treatment group, and ligation with anti-RANKL antibody + miR-146a treatment group in WT mice and TLR2/4 KO mice (a) (scale bar, 100 μm). Inflammatory cell numbers were measured and analyzed in each group of WT mice (b) and TLR2/4 KO mice (c) (mean ± SD, n = 6, **p < 0.01) : RANKL blockade alleviates peri-implant
- Fig. 5. Anti-RANKL and anti-RANKL+miR-146a treatments decreased gingival mRNA expression of TNF-α and RANKL with different patterns in experimental peri-implantitis of WT and TLR2/4 KO mice. Gingival tissues around ligatured implants and non-ligation implants were excised and processed for RT-qPCR analysis to determine mRNA level of TNF-α of WT mice (a) and TLR2/4 KO mice (b) (mean ± SD, n = 6, *p < 0.05, **p < 0.01) and mRNA level of RANKL of WT mice (c) and TLR2/4 KO mice (d) (mean ± SD, n = 6, *p < 0.05, **p < 0.01). : RANKL blockade alleviates peri-implant